Pharmacodynamics of peginterferon alfa-2a and peginterferon alfa-2b in interferon-naïve patients with chronic hepatitis C: A randomized, controlled study

Alimentary Pharmacology and Therapeutics

Volumn 26, Issue 3, 2007, Pages 369-376

  Bruno, R ^a,b   Sacchi, P ^b   Scagnolari, C ^c   Torriani, F ^d   Maiocchi, L ^b   Patruno, S ^b   Bellomi, F ^c   Filice, G ^b   Antonelli, G ^c  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; BIOLOGICAL MARKER; NEOPTERIN; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; SYNTHETASE; ALPHA2A INTERFERON; ALPHA2B INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; PEGINTERFERON ALFA-2A; PEGINTERFERON ALFA-2B; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BODY MASS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVITY; FEMALE; HEPATITIS C; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOM SAMPLE; RANDOMIZED CONTROLLED TRIAL; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; ANTIVIRAL AGENTS; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; TREATMENT OUTCOME;

EID: 34447298143     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2007.03392.x     Document Type: Article

References (34)

1. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002 347 : 975 82.
2. Hadziyannis SJ, Cheinquer H, Morgan T, et al. Peginterferon alfa-2a (40 KD) (Pegasys) in combination with ribavirin (RBV): efficacy and safety results from a phase III, randomized, double blind, multicentre study examining effect of duration of treatment and RBV dose. J Hepatol 2002 36 (Suppl. 1 1 3.
3. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001 358 : 958 65.
4. DiBisceglie AM, Hoofnagle JH. Optimal therapy of hepatitis C. Hepatology 2002 36 (Suppl. 1 121 7.
5. Bailon P, Palleroni A, Schaffer CA, et al. Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. Bioconjug Chem 2001 12 : 195 202.
6. Kozlowski A, Harris JM. Improvements in protein PEGylation: pegylated interferons for treatment of hepatitis C. J Control Release 2001 72 : 217 24.
7. Grace M, Youngster S, Gitlin G, et al. Structural and biologic characterization of pegylated recombinant IFN-alpha 2b. J Interferon Cytokine Res 2001 21 : 1103 15.
8. Wang YS, Youngster S, Grace M, Bausch J, Bordens R, Wyss DF. Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications. Adv Drug Deliv Rev 2002 54 : 547 70.
9. Bruno R, Sacchi P, Ciappina C, et al. Viral dynamics and pharmacokinetics of peginterferon alpha-2a and peginterferon alpha-2b in naive patients with chronic hepatitis C: a randomized, controlled study. Antivir Ther 2004 9 : 491 7.
10. Formann E, Jessner W, Bennett L, Ferenci P. Twice-weekly administration of peginterferon-α-2b improves viral kinetics in patients with chronic hepatitis C genotype 1. J Viral Hepat 2003 10 : 271 6.
11. Khakoo S, Glue P, Grellier L, et al. Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions. Br J Clin Pharmacol 1998 46 : 563 70.
12. Pawlotsky JM, Hovanessian A, Roudot-Thoraval F, et al. Activity of the interferon-induced 2′,5′-oligoadenylate synthetase in patients with chronic hepatitis C. J Interferon Cytokine Res 1995 15 : 57 62.
13. Wejstal R, Norkrans G, Weiland O, et al. Lymphocyte subsets and beta 2-microglobulin expression in chronic hepatitis C/non-A, non-B. Effects of interferon-alpha treatment. Clin Exp Immunol 1992 87 : 340 5.
14. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995 22 : 696 9.
15. Bruno R, Sacchi P, Maiocchi L, et al. Area-under-the-curve for peginterferon alpha-2a and peginterferon alpha-2b is not related to body weight in treatment-naive patients with chronic hepatitis C. Antivir Ther 2005 10 : 201 5.
16. Lamb MW, Martin NE. Weight-based versus fixed dosing of peginterferon (40 kDa) alfa-2a. Ann Pharmacother 2002 36 : 933 5.
17. Jen JF, Glue P, Ezzet F, et al. Population pharmacokinetic analysis of pegylated interferon alfa-2b and interferon alfa-2b in patients with chronic hepatitis C. Clin Pharmacol Ther 2001 69 : 407 21.
18. Glue P, Fang J, Rouzier-Panis R, et al. Pegylated interferon alpha-2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Clin Pharmacol Ther 2000 68 : 556 67.
19. Silva M, Poo-Ramirez JL, Wagner F, Jackson M, Laughlin M. Comparison of peginterferon α-2a and peginterferon α-2b pharmacokinetics and pharmacodynamics in COMPARE, a randomized, prospective, blinded trial. American Association for the Study of Liver Diseases : Boston, MA, 2004. [Abstract 68, p. 192a].
20. Silva M, Poo J, Wagner F, et al. A randomized trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE). J Hepatol 2006 45 : 204 13.
21. Jansen LMP, Reeesink HW. Antiviral effect of peginterferon alfa-2b and alfa-2a compared. J Hepatol 2006 45 : 172 3.
22. Algranati NE, Sy S, Modi M. A branched methoxy 40 kDa polyethylene glycol (PEG) moiety optimizes the pharmacokinetics (PK) of pegIFN α-2a (PEG-IFN) and may explain its enhanced efficacy in chronic hepatitis C (CHC). Hepatology 1999 30 : 190A.
23. Buti M, Sanchez-Avila F, Lurie Y, et al. Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin. Hepatology 2002 35 : 930 6.
24. Harris JM, Martin NE, Modi M. Pegylation a novel process for modifying pharmacokinetics. Clin Pharmacokinet 2001 40 : 539 51.
25. Herrmann E, Lee JH, Marinos G, Modi M, Zeuzem S. Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology 2003 37 : 51 8.
26. Modi MW, Fried M, Reindollar RW, et al. The pharmacokinetic behaviour of pegylated (40 kDa) interferon alfa-2a (PEGASYS®) in chronic hepatitis C patients after multiple dosing. Hepatology 2000 32 : 394A.
27. Peginterferon alfa-2a (Pegasys) Prescribing Information, Roche Laboratories Inc., Nutley, NJ, USA.
28. Peginterferon alfa-2b (PegIntron) Prescribing Information, Schering-Plough Corporation, Kenilworth NJ, USA.
29. Xu ZX, Hoffman J, Patel I, Joubert P. Single-dose safety/tolerability and pharmacokinetics/pharmacodynamics (PK/PD) following administration of ascending subcutaneous doses of pegylated-interferon (PEG-IFN) and interferon α-2a (IFNα-2a) to healthy subjects. Hepatology 1998 28 : 702A.
30. Zeuzem S, Hermann E, Lee JH, et al. Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon α-2a. Gastroenterology 2001 120 : 1438 47.
31. Zeuzem S, Welsch C, Herrmann E. Pharmacokinetics of peginterferons. Semin Liver Dis 2003 23 (Suppl. 1 23 8.
32. US Food and Drug Administration. Center for Drug Evaluation and Research. Peginterferon alfa-2a. Proceedings from the Antiviral Drugs Advisory Committee, November 14, 2002.
33. US Food and Drug Administration. Center for Drug Evaluation and Research. Peginterferon alfa-2b. Proceedings from the Antiviral Drugs Advisory Committee, December 12, 2001.
34. Poynard T, McHutchison J, Goodman Z, Ling MH, Albrecht J. Is an a la carte combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group. Hepatology 2000 31 : 211 8.